GT Biopharma, Inc. Quarterly Lessee, Operating Lease, Liability, to be Paid in USD from Q1 2022 to Q1 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of lessee's undiscounted obligation for lease payment for operating lease.
Summary
GT Biopharma, Inc. quarterly Lessee, Operating Lease, Liability, to be Paid history and growth rate from Q1 2022 to Q1 2024.
  • GT Biopharma, Inc. Lessee, Operating Lease, Liability, to be Paid for the quarter ending March 31, 2024 was $30K, a 79.6% decline year-over-year.
Lessee, Operating Lease, Liability, to be Paid, Quarterly (USD)
Lessee, Operating Lease, Liability, to be Paid, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date Report Filed
Q1 2024 $30K -$117K -79.6% Mar 31, 2024 10-Q 2024-05-15
Q4 2023 $60M +$59.8M +27937% Dec 31, 2023 10-K 2024-03-26
Q3 2023 $92K -$106K -53.5% Sep 30, 2023 10-Q 2023-11-01
Q2 2023 $120K -$97K -44.7% Jun 30, 2023 10-Q 2023-08-07
Q1 2023 $147K -$100K -40.5% Mar 31, 2023 10-Q 2023-05-15
Q4 2022 $214K Dec 31, 2022 10-K 2023-03-30
Q3 2022 $198K Sep 30, 2022 10-Q 2022-10-31
Q2 2022 $217K Jun 30, 2022 10-Q 2022-08-15
Q1 2022 $247K Mar 31, 2022 10-Q 2022-05-16
* An asterisk sign (*) next to the value indicates that the value is likely invalid.